These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26892515)

  • 21. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
    Futema M; Plagnol V; Li K; Whittall RA; Neil HA; Seed M; ; Bertolini S; Calandra S; Descamps OS; Graham CA; Hegele RA; Karpe F; Durst R; Leitersdorf E; Lench N; Nair DR; Soran H; Van Bockxmeer FM; ; Humphries SE
    J Med Genet; 2014 Aug; 51(8):537-44. PubMed ID: 24987033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Shin DG; Han SM; Kim DI; Rhee MY; Lee BK; Ahn YK; Cho BR; Woo JT; Hur SH; Jeong JO; Jang Y; Lee JH; Lee SH
    Atherosclerosis; 2015 Nov; 243(1):53-8. PubMed ID: 26343872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Familial hypercholesterolemia in Tunisia].
    Jelassi A; Jguirim I; Najah M; Maatouk F; Ben Hamda K; Slimane MN
    Pathol Biol (Paris); 2009 Jul; 57(5):444-50. PubMed ID: 19041195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.
    Drouin-Chartier JP; Tremblay AJ; Hogue JC; Ooi TC; Lamarche B; Couture P
    Metabolism; 2015 Nov; 64(11):1541-7. PubMed ID: 26371983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
    Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
    Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic characterization of two deletions in the LDLR gene in Tunisian patients with familial hypercholesterolemia.
    Jelassi A; Slimani A; Rabès JP; Jguirim I; Abifadel M; Boileau C; Najah M; M'rabet S; Mzid J; Slimane MN; Varret M
    Clin Chim Acta; 2012 Dec; 414():146-51. PubMed ID: 22910581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE.
    Jarauta E; Pérez-Ruiz MR; Pérez-Calahorra S; Mateo-Gallego R; Cenarro A; Cofán M; Ros E; Civeira F; Tejedor MT
    J Clin Lipidol; 2016; 10(6):1397-1405.e2. PubMed ID: 27919357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe.
    Stef MA; Palacios L; Olano-Martín E; Foe-A-Man C; van de Kerkhof L; Klaaijsen LN; Molano A; Schuurman EJ; Tejedor D; Defesche JC
    J Mol Diagn; 2013 May; 15(3):362-72. PubMed ID: 23537714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Pek SLT; Dissanayake S; Fong JCW; Lin MX; Chan EZL; Tang JI; Lee CW; Ong HY; Sum CF; Lim SC; Tavintharan S
    Atherosclerosis; 2018 Feb; 269():106-116. PubMed ID: 29353225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LDLR promoter variant and exon 14 mutation on the same chromosome are associated with an unusually severe FH phenotype and treatment resistance.
    Snozek CL; Lagerstedt SA; Khoo TK; Rubenfire M; Isley WL; Train LJ; Baudhuin LM
    Eur J Hum Genet; 2009 Jan; 17(1):85-90. PubMed ID: 18648394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional characterization of mutant genes associated with autosomal dominant familial hypercholesterolemia: integration and evolution of genetic diagnosis.
    Di Taranto MD; D'Agostino MN; Fortunato G
    Nutr Metab Cardiovasc Dis; 2015 Nov; 25(11):979-87. PubMed ID: 26165249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India.
    Reddy LL; Shah SAV; Ponde CK; Dalal JJ; Jatale RG; Dalal RJ; Rajani RM; Pillai SK; Vanjani CV; Ashavaid TF
    J Hum Genet; 2021 Oct; 66(10):983-993. PubMed ID: 33864011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia.
    Reeskamp LF; Hartgers ML; Peter J; Dallinga-Thie GM; Zuurbier L; Defesche JC; Grefhorst A; Hovingh GK
    Circ Genom Precis Med; 2018 Dec; 11(12):e002385. PubMed ID: 30562117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Genetic Analysis in a Chinese Cohort of 208 Patients Related to Familial Hypercholesterolemia.
    Wang H; Yang H; Liu Z; Cui K; Zhang Y; Zhang Y; Zhao K; Yin K; Li W; Zhou Z
    J Atheroscler Thromb; 2020 Dec; 27(12):1288-1298. PubMed ID: 32759540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
    Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia.
    Rieck L; Bardey F; Grenkowitz T; Bertram L; Helmuth J; Mischung C; Spranger J; Steinhagen-Thiessen E; Bobbert T; Kassner U; Demuth I
    Clin Genet; 2020 Nov; 98(5):457-467. PubMed ID: 32770674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
    Futema M; Whittall RA; Kiley A; Steel LK; Cooper JA; Badmus E; Leigh SE; Karpe F; Neil HA; ; Humphries SE
    Atherosclerosis; 2013 Jul; 229(1):161-8. PubMed ID: 23669246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.